Literature DB >> 12914522

CTLA-4 and its role in autoimmune thyroid disease.

D A Chistiakov1, R I Turakulov.   

Abstract

Autoimmune thyroid disease (AITD) occurs in two common forms: Graves' disease and Hashimoto thyroiditis. On the basis of functional and experimental data, it has been suggested that the gene encoding cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) is a candidate gene for conferring susceptibility to thyroid autoimmunity. In this review, we critically evaluate the evidence for pathogenetic involvement of CTLA-4 in the various forms of AITD and focus on the possible role of genetic variation of the CTLA4 locus. Population genetics data strongly suggest a role for the CTLA4 region in susceptibility to AITD. However, further functional studies are required to understand the significance of CTLA4 polymorphisms in the pathogenic mechanism of AITD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12914522     DOI: 10.1677/jme.0.0310021

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  40 in total

1.  Chromosome region 2p25 is linked and associated with type 1 diabetes in Colombia.

Authors:  Nicolas Pineda-Trujilo; Federico Uribe; Fabiola Montoya; Juan-Manuel Alfaro; Guillermo Latorre; Alberto Villegas; Javier Ceron; Andres-Felipe Perez; Mariano Ospina; Andres Naranjo; Abel Serrano; Ivan Duque; Debora Castrillon; Alberto Abad; Gabriel Bedoya; Vital Balthazar; Andres Ruiz-Linares
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

2.  Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.

Authors:  Charlée Nardin; Sophie Borot; Marie-Astride Beaudoin; Françoise Cattin; Eve Puzenat; Anne-Sophie Gauthier; Franck Schillo; Christophe Borg; François Aubin
Journal:  Invest New Drugs       Date:  2018-08-25       Impact factor: 3.850

3.  Exon-1 polymorphism of ctla-4 gene is not associated with systemic sclerosis in Iranian patients.

Authors:  A Rajaee; A Ebrahimi; A Fotouhi Ghiam; T Kalantari; A Ghaderi
Journal:  Rheumatol Int       Date:  2005-09-28       Impact factor: 2.631

4.  CTLA-4 gene exon-1 +49 A/G polymorphism: lack of association with autoimmune disease in patients with common variable immune deficiency.

Authors:  Adina Kay Knight; Davide Serrano; Yaron Tomer; Charlotte Cunningham-Rundles
Journal:  J Clin Immunol       Date:  2006-12-28       Impact factor: 8.317

5.  Genetics of autoimmune thyroid disease in the Lebanese population.

Authors:  C Farra; J Awwad; A Fadlallah; G Sebaly; G Hage; M Souaid; H Ashkar; R Medlej; M H Gannageh; G Halaby
Journal:  J Community Genet       Date:  2012-03-06

6.  Evidence for CTLA4 as a susceptibility gene for dilated cardiomyopathy.

Authors:  Volker Ruppert; Thomas Meyer; Clarissa Struwe; Jana Petersen; Andreas Perrot; Maximilian G Posch; Cemil Ozcelik; Anette Richter; Bernhard Maisch; Sabine Pankuweit
Journal:  Eur J Hum Genet       Date:  2010-02-10       Impact factor: 4.246

7.  CTLA-4 A49G gene polymorphism is not associated with vitiligo in South Indian population.

Authors:  Farha Deeba; Rabbani Syed; Jariya Quareen; M A Waheed; Kaiser Jamil; Hanmanth Rao
Journal:  Indian J Dermatol       Date:  2010       Impact factor: 1.494

8.  Association of -318 C/T and +49 A/G cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms with a clinical subset of Italian patients with systemic sclerosis.

Authors:  G Balbi; F Ferrera; M Rizzi; P Piccioli; A Morabito; L Cardamone; M Ghio; G L Palmisano; P Carrara; S Pedemonte; M Sessarego; M De Angioletti; R Notaro; F Indiveri; M P Pistillo
Journal:  Clin Exp Immunol       Date:  2007-04-25       Impact factor: 4.330

9.  CTLA-4 polymorphisms and systemic lupus erythematosus: a comprehensive meta-analysis.

Authors:  Jie Liu; Hong-Xin Zhang
Journal:  Genet Test Mol Biomarkers       Date:  2013-01-05

Review 10.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.